Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1173

1.

Radiomics and liquid biopsy in oncology: the holons of systems medicine.

Neri E, Del Re M, Paiar F, Erba P, Cocuzza P, Regge D, Danesi R.

Insights Imaging. 2018 Nov 14. doi: 10.1007/s13244-018-0657-7. [Epub ahead of print] Review.

PMID:
30430428
2.

Deep Learning Electronic Cleansing for Single- and Dual-Energy CT Colonography.

Tachibana R, Näppi JJ, Ota J, Kohlhase N, Hironaka T, Kim SH, Regge D, Yoshida H.

Radiographics. 2018 Nov-Dec;38(7):2034-2050. doi: 10.1148/rg.2018170173.

PMID:
30422761
3.

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Giannone G, Milani A, Geuna E, Galizia D, Biello F, Montemurro F.

Expert Opin Pharmacother. 2018 Nov 6:1-5. doi: 10.1080/14656566.2018.1543406. [Epub ahead of print] No abstract available.

PMID:
30396301
4.

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L.

Eur J Cancer. 2018 Nov 2;105:61-70. doi: 10.1016/j.ejca.2018.09.034. [Epub ahead of print]

PMID:
30396014
5.

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D.

Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018.

6.

Reproducible bioinformatics project: a community for reproducible bioinformatics analysis pipelines.

Kulkarni N, Alessandrì L, Panero R, Arigoni M, Olivero M, Ferrero G, Cordero F, Beccuti M, Calogero RA.

BMC Bioinformatics. 2018 Oct 15;19(Suppl 10):349. doi: 10.1186/s12859-018-2296-x.

7.

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Oct 11. doi: 10.1093/annonc/mdy450. [Epub ahead of print]

PMID:
30307529
8.

Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.

Castiglia S, Adamini A, Rustichelli D, Castello L, Mareschi K, Pinnetta G, Leone M, Mandese A, Ferrero I, Mesiano G, Fagioli F.

J Transl Med. 2018 Oct 10;16(1):275. doi: 10.1186/s12967-018-1656-7.

9.

Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.

Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, Di Stefano RF, Ghisoni E, Lombardi P, Mariniello A, Reale ML, Trevisi E, Leone G, Muratori L, Marcato M, Bironzo P, Novello S, Aglietta M, Scagliotti GV, Perrone F, Di Maio M.

Ann Oncol. 2018 Oct 10. doi: 10.1093/annonc/mdy449. [Epub ahead of print]

PMID:
30304498
10.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
11.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

PMID:
30285218
12.

Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.

Siravegna G, Corcoran RB.

Cancer Discov. 2018 Oct;8(10):1213-1215. doi: 10.1158/2159-8290.CD-18-0952.

PMID:
30279194
13.

Integration of transcriptomic data and metabolic networks in cancer samples reveals highly significant prognostic power.

Graudenzi A, Maspero D, Filippo MD, Gnugnolo M, Isella C, Mauri G, Medico E, Antoniotti M, Damani C.

J Biomed Inform. 2018 Sep 20. pii: S1532-0464(18)30184-9. doi: 10.1016/j.jbi.2018.09.010. [Epub ahead of print]

PMID:
30244122
14.

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation.

Virzì AR, Gentile A, Benvenuti S, Comoglio PM.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10058-10063. doi: 10.1073/pnas.1721147115. Epub 2018 Sep 17.

15.

Robotic Versus Laparoscopic Right Colectomy with Complete Mesocolic Excision for the Treatment of Colon Cancer: Perioperative Outcomes and 5-Year Survival in a Consecutive Series of 202 Patients.

Spinoglio G, Bianchi PP, Marano A, Priora F, Lenti LM, Ravazzoni F, Petz W, Borin S, Ribero D, Formisano G, Bertani E.

Ann Surg Oncol. 2018 Sep 14. doi: 10.1245/s10434-018-6752-7. [Epub ahead of print]

PMID:
30218248
16.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M.

Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.

PMID:
30217671
17.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino M.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.1390.2018. doi: 10.1158/1078-0432.CCR-18-1390. [Epub ahead of print]

PMID:
30206165
18.

Kinesin-2 Controls the Motility of RAB5 Endosomes and Their Association with the Spindle in Mitosis.

Pupo E, Avanzato D, Scianna M, Oldani A, Serini G, Lanzetti L.

Int J Mol Sci. 2018 Aug 30;19(9). pii: E2575. doi: 10.3390/ijms19092575.

19.

Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study.

Castello LM, Leone M, Adamini A, Castiglia S, Mareschi K, Ferrero I, Marco G, Carnevale-Schianca F, Fagioli F, Berger M.

J Pediatr Hematol Oncol. 2018 Nov;40(8):e486-e489. doi: 10.1097/MPH.0000000000001305.

PMID:
30188352
20.

Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.

Merlano MC, Merlotti AM, Licitra L, Denaro N, Fea E, Galizia D, Di Maio M, Fruttero C, Curcio P, Vecchio S, Russi EG, Corvò R.

Clin Transl Radiat Oncol. 2018 Aug 13;12:47-52. doi: 10.1016/j.ctro.2018.08.001. eCollection 2018 Aug.

Supplemental Content

Loading ...
Support Center